Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591)
Hong Kong
· Delayed Price · Currency is HKD
16.38
+1.14 (7.48%)
Apr 29, 2026, 4:08 PM HKT
HKG:2591 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Revenue | 131.51 | - | - |
| Cost of Revenue | 14.45 | - | - |
| Gross Profit | 117.06 | - | - |
| Selling, General & Admin | 254.05 | 86.85 | 255.74 |
| Research & Development | 205.78 | 102.51 | 492.11 |
| Other Operating Expenses | 4.05 | 0.06 | 0.06 |
| Operating Expenses | 463.88 | 189.42 | 747.91 |
| Operating Income | -346.82 | -189.42 | -747.91 |
| Interest Expense | -1.72 | -0.87 | -2.32 |
| Interest & Investment Income | 13.5 | 14.8 | 13.97 |
| Currency Exchange Gain (Loss) | -6.5 | 0.7 | 0.71 |
| Other Non Operating Income (Expenses) | 0.18 | 0.21 | 1.05 |
| EBT Excluding Unusual Items | -341.36 | -174.58 | -734.5 |
| Gain (Loss) on Sale of Investments | - | 0.19 | 1.13 |
| Gain (Loss) on Sale of Assets | - | -4.45 | - |
| Other Unusual Items | - | 4.15 | - |
| Pretax Income | -341.36 | -174.69 | -733.38 |
| Net Income | -341.36 | -174.69 | -733.38 |
| Net Income to Common | -341.36 | -174.69 | -733.38 |
| Shares Outstanding (Basic) | 434 | 420 | 383 |
| Shares Outstanding (Diluted) | 434 | 420 | 383 |
| Shares Change (YoY) | 3.44% | 9.63% | - |
| EPS (Basic) | -0.79 | -0.42 | -1.92 |
| EPS (Diluted) | -0.79 | -0.42 | -1.92 |
| Free Cash Flow | - | -166.57 | -176.64 |
| Free Cash Flow Per Share | - | -0.40 | -0.46 |
| Gross Margin | 89.01% | - | - |
| Operating Margin | -263.72% | - | - |
| Profit Margin | -259.57% | - | - |
| EBITDA | -332.31 | -174.91 | -733.76 |
| EBITDA Margin | -252.69% | - | - |
| D&A For EBITDA | 14.51 | 14.51 | 14.14 |
| EBIT | -346.82 | -189.42 | -747.91 |
| EBIT Margin | -263.72% | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.